Update shared on 13 Nov 2025
Analysts maintained their price target for Rubicon Organics at $1.15. This reflects stable expectations, despite minor adjustments to sector discount rates and growth assumptions.
What's in the News
- Rubicon Organics Inc. received a cultivation, processing, and storage license for its Cascadia facility in Hope, British Columbia from Health Canada (Key Developments).
- The Cascadia facility spans 47,500 square feet and is equipped with advanced cultivation technologies (Key Developments).
- This expansion provides an additional 4,500 kg of production capacity, representing a 40% increase. The total annual output is now 15,500 kg of premium cannabis (Key Developments).
- Operations at the new facility have commenced, and the first revenue is expected in the first half of 2026 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at CA$1.15. This reflects ongoing stability in valuation expectations.
- The discount rate has risen slightly from 5.97% to 6.12%, indicating a minor increase in required returns for investors.
- The revenue growth projection is effectively unchanged and holds steady at approximately 12.85%.
- The net profit margin forecast remains stable at 5.39%, with negligible adjustment from previous estimates.
- The future P/E ratio has increased marginally from 26.32x to 26.43x, signaling a slight adjustment in forward earnings expectations.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.